When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ACHN - Achillion achieves enrollment milestone in phase 2 trials for C3G
Achison Inc Cl A
Achillion Pharmaceuticals (NASDAQ:ACHN) has enrolled 23 patients in Phase 2 ACH-4471 six and 12-month clinical trials for patients with C3 glomerulopathy (C3G), a disease affecting the kidney for which there is no approved therapy.
More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,